Spectral AI, Inc.
MDAIW
NASDAQ0.48
USD
-0.01
- -
Spectral AI, Inc.
MDAIW
(NASDAQ)
Recent
price
0.48
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Spectral AI, Inc. is a Dallas-based predictive artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial commercial applications in burn care; the company develops and commercializes the DeepView® System, a non-invasive, algorithm-driven diagnostic platform that combines multispectral imaging and proprietary AI to assess wound healing potential and support earlier treatment decisions for clinicians in burn centers, trauma centers, emergency departments and other care settings. Founded in 2009 and headquartered in Dallas, Texas, Spectral AI also maintains operations in the United Kingdom and markets its technology for potential use in burn wound assessment and broader wound-care applications, including future indications. In 2026, the company reached a major commercial inflection point after receiving FDA De Novo clearance for the DeepView System for burn indication, authorizing U.S. commercial distribution and positioning the platform for first commercial sales by year-end 2026. During the same period, Spectral AI secured $31.7 million of advanced BARDA funding to support additional DeepView development and procurement, drew $6.5 million under its Avenue Capital Group credit facility, completed remaining milestones under a Department of Defense contract through MTEC, expanded its leadership team with the appointments of David McGuire as chief financial officer and Darcy Bajko as chief commercial officer, and began a label-expansion study in the United Kingdom to extend the DeepView System to heads, hands and feet and support additional authorization in the United Kingdom, Australia or Gulf Cooperation Council countries. The company continues to report development and pre-commercial revenue primarily from government contracts, while advancing its transition from a research and development business toward commercial sales of its FDA-cleared DeepView burn-assessment system.
Company News
Spectral AI Showcases DeepView® System for Burn Indication and KOL Research at Southern Regional Burn Conference
Spectral AI Schedules 2026 Second Quarter Financial Results and Conference Call
Spectral AI Names Darcy Bajko Chief Commercial Officer to Lead Global Sales Launch of FDA-Cleared DeepView® System for Burn Indication
Spectral AI to Participate in 2026 British Burn Association Annual Conference
Spectral AI, Inc. (MDAI) Q1 2026 Earnings Call Transcript
Spectral AI (NASDAQ:MDAIW) Shares Down 8.6% – Should You Sell?